The Medicines and Healthcare products Regulatory Agency (MHRA) has approved 55 microgram Nasacort Allergy Relief nasal spray for general sale.
The MHRA’s latest move follows the application from the product licence holder, Aventis Pharma Limited, to change the legal status of the product from a Pharmacy (P) medicine to a General Sales List (GSL) medicine.
The nasal spray or solution is indicated for the relief of symptoms associated with seasonal allergic rhinitis (SAR) in adults aged 18 years and over.
In its latest public assessment report (PAR), the MHRA has confirmed the product sufficiently safe to be sold on general sale.
Each spray contains 55 micrograms of triamcinolone acetonide.
It has also outlined the evidence that the MHRA reviewed and which led to the decision to approve the application.
The SAR symptoms include sneezing, itchy and runny nose, itchy, red or watery eyes, nasal congestion or associated sinus discomfort.
Allergic rhinitis is inflammation of the inside of the nose caused by an allergen and an allergen is a substance that causes an allergic response.
‘Seasonal’ allergic rhinitis is when symptoms occur at the same time each year in response to a seasonal allergen, including grass and tree pollen allergens.